• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4837395)   Today's Articles (8689)
For: Bamias A, Davis ID, Galsky MD, Arranz JÁ, Kikuchi E, Grande E, Del Muro XG, Park SH, De Giorgi U, Alekseev B, Mencinger M, Izumi K, Schutz FA, Puente J, Li JR, Panni S, Gumus M, Özgüroğlu M, Mariathasan S, Poloz Y, Bene-Tchaleu F, Lee C, Bernhard S, De Santis M. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study. Lancet Oncol 2024;25:46-61. [PMID: 38101431 DOI: 10.1016/s1470-2045(23)00539-9] [Citation(s) in RCA: 21] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Revised: 10/12/2023] [Accepted: 10/16/2023] [Indexed: 12/17/2023]
Number Cited by Other Article(s)
1
Poon DM, Chiu PK, Chan MT, Ho BS, Law K, Leung AK, Leung CL, Na R, Wong KC, Wu PY, Kwong PW, Teoh JY. Consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology on the management of muscle-invasive and advanced urothelial carcinoma. Front Oncol 2025;15:1564487. [PMID: 40406240 PMCID: PMC12095001 DOI: 10.3389/fonc.2025.1564487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2025] [Accepted: 04/10/2025] [Indexed: 05/26/2025]  Open
2
Xie J, Mao QY, Chen JH, Shi HJ, Zhan PQ, Wang HF. Efficacy and safety of atezolizumab in the treatment of urothelial carcinoma: a systematic review and meta-analysis. World J Surg Oncol 2025;23:133. [PMID: 40205427 PMCID: PMC11983893 DOI: 10.1186/s12957-025-03795-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2025] [Accepted: 03/29/2025] [Indexed: 04/11/2025]  Open
3
Galsky MD, Kockx M, Roels J, Van Elzen R, Guan X, Yuen K, Rishipathak D, Anker JF, Gnjatic S, Izadmehr S, Sanjabi S, Johnston RJ, Peterson M, Koeppen H, David JM, Gupta S, Bamias A, Arranz JA, Kikuchi E, De Santis M, Davis ID, Williams P, Bernhard S, Mellman I, Grande E, Banchereau R, Mariathasan S. Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer. Cancer Immunol Res 2025;13:476-486. [PMID: 39853278 PMCID: PMC11962399 DOI: 10.1158/2326-6066.cir-24-0649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2024] [Revised: 10/03/2024] [Accepted: 01/22/2025] [Indexed: 01/26/2025]
4
Grande E, Hussain SA, Barthélémy P, Kanesvaran R, Giannatempo P, Benjamin DJ, Hoffman J, Birtle A. Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians. Cancer Treat Rev 2025;134:102900. [PMID: 39999590 DOI: 10.1016/j.ctrv.2025.102900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2024] [Revised: 02/07/2025] [Accepted: 02/08/2025] [Indexed: 02/27/2025]
5
Catanzaro E, Beltrán-Visiedo M, Galluzzi L, Krysko DV. Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors. Cell Mol Immunol 2025;22:24-39. [PMID: 39653769 PMCID: PMC11685666 DOI: 10.1038/s41423-024-01245-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2024] [Accepted: 11/18/2024] [Indexed: 12/13/2024]  Open
6
Zhang T, Tan A, Shah AY, Iyer G, Morris V, Michaud S, Sridhar SS. Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma. Oncologist 2024;29:1003-1013. [PMID: 39167703 PMCID: PMC11630754 DOI: 10.1093/oncolo/oyae215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2024] [Accepted: 07/17/2024] [Indexed: 08/23/2024]  Open
7
Rosenberg JE, Galsky MD, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, van der Heijden MS, Dreicer R, Durán I, Castellano D, Drakaki A, Retz M, Sridhar SS, Grivas P, Yu EY, O'Donnell PH, Burris HA, Mariathasan S, Shi Y, Goluboff E, Bajorin D. Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial. ESMO Open 2024;9:103972. [PMID: 39642637 PMCID: PMC11667038 DOI: 10.1016/j.esmoop.2024.103972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2024] [Accepted: 10/01/2024] [Indexed: 12/09/2024]  Open
8
Roviello G, Santoni M, Sonpavde GP, Catalano M. The evolving treatment landscape of metastatic urothelial cancer. Nat Rev Urol 2024;21:580-592. [PMID: 38702396 DOI: 10.1038/s41585-024-00872-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/11/2024] [Indexed: 05/06/2024]
9
Li K, Zhong W, Fan J, Wang S, Yu D, Xu T, Lyu J, Wu S, Qin T, Wu Z, Xu L, Wu K, Liu Z, Hu Z, Li F, Wang J, Wang Q, Min J, Zhang Z, Yu L, Ding S, Huang L, Zhao T, Huang J, Lin T. Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial. NATURE CANCER 2024;5:1465-1478. [PMID: 39256488 DOI: 10.1038/s43018-024-00822-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/09/2023] [Accepted: 08/09/2024] [Indexed: 09/12/2024]
10
Zhao Y, Xu X, Sun Y, Yu X, Qi Y, Dai X. Efficacy and safety of the first-line systemic treatments in patients with advanced-stage urothelial carcinoma: a systematic review and network meta-analysis. Front Oncol 2024;14:1468784. [PMID: 39351347 PMCID: PMC11439625 DOI: 10.3389/fonc.2024.1468784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2024] [Accepted: 08/29/2024] [Indexed: 10/04/2024]  Open
11
Xiang G, Huang Y, Gan L, Wang L, Ding Y, Wu Y, Xing H, Liu Y. Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States. Front Immunol 2024;15:1426024. [PMID: 39346914 PMCID: PMC11427378 DOI: 10.3389/fimmu.2024.1426024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2024] [Accepted: 08/27/2024] [Indexed: 10/01/2024]  Open
12
Liu Q, Guan Y, Li S. Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the "all-around warrior" in immunotherapy. Mol Cancer 2024;23:183. [PMID: 39223527 PMCID: PMC11367915 DOI: 10.1186/s12943-024-02095-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2024] [Accepted: 08/18/2024] [Indexed: 09/04/2024]  Open
13
Zhang M, Wu J, Zhang Y, Shang H. Recent Advances of Neoadjuvant Immunotherapy for Urothelial Bladder Cancer. Ann Surg Oncol 2024;31:5851-5859. [PMID: 38995447 DOI: 10.1245/s10434-024-15725-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2024] [Accepted: 06/19/2024] [Indexed: 07/13/2024]
14
Gasperoni L, Del Bono L, Ossato A, Giunta EF, Messori A, Damuzzo V. A Head-to-Head Comparison of the First-Line Treatments for Locally Advanced or Metastatic Urothelial Cancer: Is There Still a Role for Chemotherapy? Cancers (Basel) 2024;16:2400. [PMID: 39001462 PMCID: PMC11240305 DOI: 10.3390/cancers16132400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2024] [Revised: 06/24/2024] [Accepted: 06/27/2024] [Indexed: 07/16/2024]  Open
15
Germanà E, Pepe L, Pizzimenti C, Ballato M, Pierconti F, Tuccari G, Ieni A, Giuffrè G, Fadda G, Fiorentino V, Martini M. Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications. Int J Mol Sci 2024;25:6750. [PMID: 38928456 PMCID: PMC11203574 DOI: 10.3390/ijms25126750] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2024] [Revised: 06/17/2024] [Accepted: 06/18/2024] [Indexed: 06/28/2024]  Open
16
Seema Mustafa, Jansen CS, Jani Y, Evans S, Zhuang TZ, Brown J, Nazha B, Master V, Bilen MA. The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers. Biomark Insights 2024;19:11772719241254179. [PMID: 38827239 PMCID: PMC11143877 DOI: 10.1177/11772719241254179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Accepted: 04/24/2024] [Indexed: 06/04/2024]  Open
17
Zhao J, Wang Q, Tan AF, Loh CJL, Toh HC. Sex differences in cancer and immunotherapy outcomes: the role of androgen receptor. Front Immunol 2024;15:1416941. [PMID: 38863718 PMCID: PMC11165033 DOI: 10.3389/fimmu.2024.1416941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2024] [Accepted: 05/16/2024] [Indexed: 06/13/2024]  Open
18
Larroquette M, Lefort F, Domblides C, Héraudet L, Robert G, Ravaud A, Gross-Goupil M. How Immunotherapy Has Redefined the Treatment Paradigm of Metastatic or Locally Advanced Muscle-Invasive Urothelial Bladder Carcinoma. Cancers (Basel) 2024;16:1780. [PMID: 38730732 PMCID: PMC11083785 DOI: 10.3390/cancers16091780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2024] [Revised: 05/01/2024] [Accepted: 05/02/2024] [Indexed: 05/13/2024]  Open
19
Young M. The Future of Front-line Metastatic Bladder Cancer is Platinum-free. Eur Urol Focus 2024;10:215-216. [PMID: 38658299 DOI: 10.1016/j.euf.2024.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2024] [Accepted: 04/12/2024] [Indexed: 04/26/2024]
20
Grande E, Arranz JÁ, De Santis M, Bamias A, Kikuchi E, Del Muro XG, Park SH, De Giorgi U, Alekseev B, Mencinger M, Izumi K, Schutz FA, Puente J, Li JR, O'Donnell PH, Kalebasty AR, Ye D, Mariathasan S, Bene-Tchaleu F, Bernhard S, Lee C, Davis ID, Galsky MD. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study. Lancet Oncol 2024;25:29-45. [PMID: 38101433 DOI: 10.1016/s1470-2045(23)00540-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Revised: 10/12/2023] [Accepted: 10/16/2023] [Indexed: 12/17/2023]
21
Siefker-Radtke AO, Desai M. Evolution of front-line immunotherapy for metastatic urothelial cancer. Lancet Oncol 2024;25:2-3. [PMID: 38101432 DOI: 10.1016/s1470-2045(23)00633-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2023] [Revised: 12/04/2023] [Accepted: 12/04/2023] [Indexed: 12/17/2023]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA